CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report)’s stock price traded up 2.7% during trading on Friday . The stock traded as high as $2.35 and last traded at $2.26. 2,686 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 33,735 shares. The stock had previously closed at $2.20.
Analyst Ratings Changes
Separately, Benchmark restated a “speculative buy” rating and set a $5.00 price objective on shares of CytoMed Therapeutics in a research note on Thursday, October 10th.
Read Our Latest Stock Report on CytoMed Therapeutics
CytoMed Therapeutics Stock Up 2.7 %
CytoMed Therapeutics Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Featured Articles
- Five stocks we like better than CytoMed Therapeutics
- Stock Market Sectors: What Are They and How Many Are There?
- Tesla Investors Continue to Profit From the Trump Trade
- Energy and Oil Stocks Explained
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
